Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Marburg Hemorrhagic Fever - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Marburg Hemorrhagic Fever - Pipeline Review, H1 2016', provides an overview of the Marburg Hemorrhagic Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marburg Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburg Hemorrhagic Fever and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever - The report reviews pipeline therapeutics for Marburg Hemorrhagic Fever by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Marburg Hemorrhagic Fever therapeutics and enlists all their major and minor projects - The report assesses Marburg Hemorrhagic Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Marburg Hemorrhagic Fever Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Marburg Hemorrhagic Fever Overview 9 Therapeutics Development 10 Pipeline Products for Marburg Hemorrhagic Fever - Overview 10 Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis 11 Marburg Hemorrhagic Fever - Therapeutics under Development by Companies 12 Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 13 Marburg Hemorrhagic Fever - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Marburg Hemorrhagic Fever - Products under Development by Companies 16 Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes 17 Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development 18 Arbutus Biopharma Corporation 18 Arno Therapeutics, Inc. 19 BioCryst Pharmaceuticals, Inc. 20 Crucell N.V. 21 GeoVax Labs, Inc. 22 GlaxoSmithKline Plc 23 Immunovaccine, Inc. 24 Integrated BioTherapeutics, Inc. 25 NanoViricides, Inc. 26 Profectus BioSciences, Inc. 27 Sarepta Therapeutics, Inc. 28 Marburg Hemorrhagic Fever - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 (Ebola + Marburg) (monovalent) vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 (Ebola + Marburg) (trivalent) vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 (Ebola + Marburg) vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 (Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 1-E703 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Antibodies for Ebola and Marburg Viral Infections - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AR-12 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ARD-5 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 AVI-7288 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BCX-4430 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Ebola vaccine + Marburg vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 FDX-000 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 GOVXE-301 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 GOVXE-302 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 imatinib mesylate - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Marburg vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Marburg vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Monoclonal Antibody for Marburg Virus - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 nilotinib - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Small molecule for Ebola and Marburg Infections - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Small Molecules for Ebola and Marburg Infections - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 TKM-Marburg - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Marburg Hemorrhagic Fever - Recent Pipeline Updates 71 Marburg Hemorrhagic Fever - Dormant Projects 81 Marburg Hemorrhagic Fever - Discontinued Products 82 Marburg Hemorrhagic Fever - Product Development Milestones 83 Featured News & Press Releases 83 Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform 83 Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate 84 Nov 12, 2013: Tekmira Announces New Preclinical Data On TKM-Marburg 84 Oct 08, 2013: Tekmira Provides Corporate Update On RNAi Therapeutics Product TKM-Marburg 85 Sep 25, 2013: Tekmira Presents New Anti-Viral Efficacy Data Against the Marburg Hemorrhagic Fever Virus 86 Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease 87 May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus 87 Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates 88 Appendix 90 Methodology 90 Coverage 90 Secondary Research 90 Primary Research 90 Expert Panel Validation 90 Contact Us 90 Disclaimer 91
List of Tables
Number of Products under Development for Marburg Hemorrhagic Fever, H1 2016 10 Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Marburg Hemorrhagic Fever - Pipeline by Arbutus Biopharma Corporation, H1 2016 18 Marburg Hemorrhagic Fever - Pipeline by Arno Therapeutics, Inc., H1 2016 19 Marburg Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2016 20 Marburg Hemorrhagic Fever - Pipeline by Crucell N.V., H1 2016 21 Marburg Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H1 2016 22 Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline Plc, H1 2016 23 Marburg Hemorrhagic Fever - Pipeline by Immunovaccine, Inc., H1 2016 24 Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 25 Marburg Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H1 2016 26 Marburg Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H1 2016 27 Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H1 2016 28 Assessment by Monotherapy Products, H1 2016 29 Assessment by Combination Products, H1 2016 30 Number of Products by Stage and Target, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 34 Number of Products by Stage and Route of Administration, H1 2016 36 Number of Products by Stage and Molecule Type, H1 2016 38 Marburg Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H1 2016 71 Marburg Hemorrhagic Fever - Dormant Projects, H1 2016 81 Marburg Hemorrhagic Fever - Discontinued Products, H1 2016 82
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.